Oruka Therapeutics, Inc. (ORKA) Current Ratio
- Current ratio · latest quarter: Value 38.51×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 38.51× | Current assets / current liabilities. $884.56M ÷ $22.97M ≈ 38.51× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 884.56M USD | Assets, Current |
| Current obligations | 22.97M USD | Liabilities, Current |
| Cash and equivalents | 268.47M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 605.09M USD | Marketable Securities, Current · Debt Securities, Available-for-sale, Current |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | (m) | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $884.56M | $22.97M | $268.47M | $605.09M | (m) | (m) | (m) | (m) | 38.51× |
| 2026-03-31 | $395.25M | $16.63M | $49.52M | $339.31M | (m) | (m) | (m) | (m) | 23.76× |
| 2025-12-31 | $343.86M | $15.37M | $46.94M | $290.11M | (m) | (m) | (m) | (m) | 22.37× |
| 2025-09-30 | $355.16M | $20.97M | $91.25M | $257.90M | (m) | (m) | (m) | (m) | 16.94× |
| 2025-06-30 | $332.01M | $12.11M | $65.40M | $263.01M | (m) | (m) | (m) | (m) | 27.42× |
| 2025-03-31 | $352.08M | $11.72M | $83.57M | $265.52M | (m) | (m) | (m) | (m) | 30.03× |
| 2024-12-31 | $376.87M | $13.04M | $61.58M | $314.07M | (m) | (m) | (m) | (m) | 28.89× |
| 2024-09-30 | $412.95M | $18.04M | $410.88M | (m) | (m) | (m) | (m) | (m) | 22.89× |
| 2024-06-30 | $33.82M | $1.27M | $33.28M | (m) | (m) | (m) | $571.00K | (m) | 26.61× |
| 2024-03-31 | $36.67M | $1.58M | $35.90M | (m) | (m) | (m) | $529.00K | (m) | 23.19× |
| 2023-12-31 | $37.59M | $637.00K | $37.43M | (m) | (m) | (m) | $362.00K | (m) | 59.01× |
| 2023-09-30 | $38.89M | $992.00K | $38.49M | (m) | (m) | (m) | $322.00K | (m) | 39.21× |
| 2023-06-30 | $40.76M | $1.60M | $40.16M | (m) | (m) | (m) | $241.00K | (m) | 25.44× |
| 2023-03-31 | $41.70M | $1.27M | $40.85M | (m) | (m) | (m) | $366.00K | (m) | 32.94× |
| 2022-12-31 | $42.70M | $1.13M | $42.45M | (m) | (m) | (m) | $334.00K | (m) | 37.72× |
| 2022-09-30 | $44.55M | $1.94M | $43.94M | (m) | (m) | (m) | $593.00K | (m) | 23.00× |
| 2022-06-30 | $47.66M | $2.81M | $46.44M | (m) | (m) | (m) | $1.11M | (m) | 16.97× |
| 2022-03-31 | $50.54M | $2.72M | $49.06M | (m) | (m) | (m) | $1.01M | (m) | 18.59× |
| 2021-12-31 | $54.42M | $3.50M | $53.36M | (m) | (m) | (m) | $1.12M | (m) | 15.56× |
| 2021-09-30 | $59.67M | $3.18M | $58.31M | (m) | (m) | (m) | $1.13M | (m) | 18.75× |
| 2021-06-30 | $64.79M | $3.69M | $63.20M | (m) | (m) | (m) | $2.19M | (m) | 17.54× |
| 2021-03-31 | $68.73M | $2.88M | $66.93M | (m) | (m) | (m) | $1.58M | (m) | 23.86× |
| 2020-12-31 | $49.97M | $3.50M | $49.07M | (m) | (m) | (m) | $1.77M | (m) | 14.28× |
| 2020-09-30 | $51.94M | $1.53M | $51.09M | (m) | (m) | (m) | $761.00K | (m) | 34.01× |
| 2020-06-30 | $11.57M | $1.33M | $11.04M | (m) | (m) | (m) | $576.00K | (m) | 8.71× |
| 2020-03-31 | $7.38M | $1.16M | $6.67M | (m) | (m) | (m) | $167.00K | (m) | 6.39× |
| 2019-12-31 | $8.48M | $926.00K | $8.36M | (m) | (m) | (m) | $418.00K | (m) | 9.16× |
| 2019-09-30 | $9.90M | $1.15M | $9.64M | (m) | (m) | (m) | $135.00K | (m) | 8.61× |
| 2019-06-30 | $10.32M | $1.20M | $9.97M | (m) | (m) | (m) | $254.00K | (m) | 8.61× |
| 2019-03-31 | $8.52M | $1.29M | $8.01M | (m) | (m) | (m) | $260.00K | (m) | 6.61× |
| 2018-12-31 | $6.78M | $793.00K | $6.61M | (m) | (m) | (m) | $230.00K | (m) | 8.55× |
| 2018-09-30 | $8.39M | $978.00K | $8.06M | (m) | (m) | (m) | $217.00K | (m) | 8.58× |
| 2018-06-30 | $10.01M | $1.06M | $9.63M | (m) | (m) | (m) | $406.00K | (m) | 9.44× |
| 2018-03-31 | $12.73M | $1.72M | $12.10M | (m) | (m) | (m) | $772.00K | (m) | 7.40× |
| 2017-12-31 | $12.30M | $2.07M | $8.70M | $3.05M | (m) | (m) | $622.00K | (m) | 5.94× |
| 2017-09-30 | $16.38M | $2.54M | $8.14M | $7.81M | (m) | (m) | $1.24M | (m) | 6.44× |
| 2017-06-30 | $16.66M | $2.52M | $9.10M | $6.91M | (m) | (m) | $1.07M | (m) | 6.61× |
| 2017-03-31 | $19.85M | $2.52M | $6.17M | $13.04M | (m) | (m) | $980.00K | (m) | 7.88× |
| 2016-12-31 | $21.45M | $2.40M | $7.40M | $13.76M | (m) | (m) | $1.21M | (m) | 8.95× |
| 2016-09-30 | $23.79M | $2.16M | $8.10M | $15.37M | (m) | (m) | $1.14M | (m) | 11.03× |
| 2016-06-30 | $26.73M | $1.70M | $14.38M | $11.98M | (m) | (m) | $760.00K | (m) | 15.75× |
| 2016-03-31 | $31.02M | $2.34M | $29.72M | $910.00K | (m) | (m) | $744.00K | (m) | 13.23× |
| 2015-12-31 | $38.92M | $1.50M | $38.80M | (m) | (m) | (m) | $364.00K | (m) | 25.88× |
| 2015-09-30 | $41.69M | $1.30M | $41.48M | (m) | (m) | (m) | $647.00K | (m) | 31.97× |
| 2015-06-30 | $44.33M | $1.36M | $44.09M | (m) | (m) | (m) | $714.00K | (m) | 32.69× |
| 2015-03-31 | $12.67M | $1.13M | $12.18M | (m) | (m) | (m) | $651.00K | (m) | 11.19× |
| 2014-12-31 | $15.49M | $1.39M | $15.35M | (m) | (m) | (m) | $795.00K | (m) | 11.16× |
| 2014-09-30 | $17.46M | $838.00K | $17.25M | (m) | (m) | (m) | $365.00K | (m) | 20.84× |
| 2014-06-30 | $19.68M | $1.22M | $19.38M | (m) | (m) | (m) | $725.00K | (m) | 16.17× |
| 2014-03-31 | $21.80M | $1.12M | $21.20M | (m) | (m) | (m) | $552.00K | (m) | 19.47× |
| 2013-12-31 | $16.93M | $1.50M | $16.76M | (m) | (m) | (m) | $597.00K | (m) | 11.27× |
| 2013-09-30 | $19.01M | $769.00K | $18.63M | (m) | (m) | (m) | $447.00K | (m) | 24.72× |
| 2013-06-30 | $20.66M | $750.00K | $20.37M | (m) | (m) | (m) | $387.00K | (m) | 27.54× |
| 2013-03-31 | $3.99M | $828.00K | $3.54M | (m) | (m) | (m) | $377.00K | (m) | 4.82× |
| 2012-12-31 | $3.04M | $305.00K | $2.92M | (m) | (m) | (m) | $65.00K | (m) | 9.98× |
| 2012-09-30 | $3.27M | $286.00K | $3.08M | (m) | (m) | (m) | $119.00K | (m) | 11.42× |
| 2012-06-30 | $3.59M | $529.00K | $3.18M | (m) | (m) | (m) | $227.00K | (m) | 6.79× |
| 2012-03-31 | $4.70M | $594.00K | $4.23M | (m) | (m) | (m) | $126.00K | (m) | 7.92× |
| 2011-12-31 | $6.21M | $754.00K | $5.94M | (m) | (m) | (m) | $260.00K | (m) | 8.24× |
| 2011-09-30 | $6.09M | $661.00K | $5.75M | (m) | (m) | (m) | $284.00K | (m) | 9.21× |
| 2011-06-30 | $7.83M | $1.00M | $7.46M | (m) | (m) | (m) | $517.00K | (m) | 7.80× |
| 2010-12-31 | $7.16M | $1.19M | $7.03M | (m) | (m) | (m) | $388.00K | (m) | 6.02× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Veradermics, Inc (MANE) | United States | $4.839B |